

National Center for HIV/AIDS, Dermatology and STD (NCHADS)

IMPLEMENTING LONG-ACTING PREP IN CAMBODIA: HOW TO GET THERE?

Dr. Ngauv Bora, Deputy Director of NCHADS/MoH



Content

- I. HIV Epidemiology in Cambodia
- II. PrEP implementation and result
- III. Background long-acting PrEP rationale
- V. Cambodia roadmap of Long-acting PrEP
- V. Monitoring and Evaluation




I. HIV Epidemiology in Cambodia




HIV Epidemiology - Snapshot and Trends 2022

Estimated people living with HIV, new HIV infections and AIDS-related deaths, 1990-2022



Distribution of new HIV infections by population, 2022




83% of an estimated 1,300 new adult HIV infections in 2022 are among key populations and their partners/clients



Summary of the AIDS epidemic in Cambodia | 2022

76,000



86%



99%



97%



Cambodia HIV Prevalence



Adult population aged 15-49 AEM 2023



5.5%
MSM IBBS 2023
Primary Data



Primary Data








HIV elimination target by 2025

2022



New adult HIV infections



- * test the right people
- * treat and retain all positives
- * **PrEP** for all sexually active KPs

Estimated KP Population Size (2023) =160,763













2025



New HIV infection


MSM 1: Known risk/high risk and reachable online and physical MSM 2: Unknown risk/ not known to be reached by programme




II. PrEP implementation and result




History of PrEP implementation




PrEP Uptake July 2019 - March 2024





Total Ever on PrEP Disaggregation by KP




PrEP active rate: 48%



Where we are in terms of KP PSE, target and PrEP enrollment?

KP Population Size Estimation (PSE) in Cambodia, 2022 (N=160,763)





III. Background Long-acting PrEP


- To attain these **ambitious targets**, especially for young KPs, PrEP options (oral and long acting) and delivery modalities must be tailored to both reach and meet the needs of these young people.
 - Not all are willing or have the time and availability to attend government or other clinics with traditional working hours¹.
 - Some guard their privacy and do not want to attend CBO Drop-in-Center (DIC) PrEP sites nor do they want to have pills that that others might see
 - Others bore quickly of waits and repeat visits in clinics and DICs and drop out of care despite continuing need¹.
 - Some cannot afford the necessary repeated transport costs¹
 - Some cannot remember to the pills
 - Long-acting PrEP
 - Injectable CAB: Injectable cabotegravir offers solutions to some of these challenges particularly the issue of privacy related to pill taking and remembering to take the pills. Clinic visits will still be required for injections every two months.
 - Dapivirine ring: is a female-initiated option for HIV prevention. The silicone ring is easy to bend and insert inside the vagina. When used as directed, the DVR acts locally within the vagina to reduce the risk of HIV acquisition for the user during vaginal sex. It is worn for 28 days and slowly releases the antiretroviral drug Dapivirine. After 28 days, it should be replaced by a new ring.

IV. Long-Acting PrEP Roadmap in Cambodia

Injectable CAB:


assessment

Recommendation



IV. Long-Acting PrEP Roadmap in Cambodia

Dapivirine vaginal ring:



V. Monitoring and Evaluation

The NCHADS through Prevention Care and Treatment-TWG: will monitor the progress of CAB-PrEP roll out plan, especially long-acting PrEP, ensuring safety, and assessing acceptability and efficacy:

- 1. Safety Monitoring:
- 2. Implementation effectiveness:
- 3. Acceptability and user experience:
- 4. Provider training and support:
- 5. Data collection and reporting:
- 6. Adaptive learning and course correction:
- 7. Quality assurance:
- 8. Community engagement:
- 9. Coordination and collaboration



Thank you